论文部分内容阅读
目的:了解鲍曼不动杆菌整合子分布情况,探讨发现的整合子与其耐药性的关系。方法:分离2014—2015年重症监护室(ICU)多重耐药鲍曼不动杆菌,用VITEK2全自动微生物鉴定系统进行菌种鉴定及药敏检测,聚合酶链反应(PCR)检测整合子可变区。结果:鲍曼不动杆菌对ICU常用药物除头孢哌酮舒巴坦外耐药率均超过50%,整合子结构的检出率为82.81%,可变区包含arr-3+aacA4和aacA4+catB8+aadA1,属于两种Ⅰ类整合子。结论:ICU的多重耐药鲍曼不动杆菌广泛存在Ⅰ类整合子结构,介导对氨基糖苷类、氯霉素和利福平耐药,对ICU多重耐药鲍曼不动杆菌的耐药基因有待进一步检测。
Objective: To understand the distribution of Acinetobacter baumannii integrants and explore the relationship between the integron and its resistance. Methods: The multi-drug resistant Acinetobacter baumannii isolated from intensive care unit (ICU) in 2014-2015 was isolated and identified by VITEK2 automatic microbial identification system. The polymerase chain reaction (PCR) Area. Results: The drug resistance rate of Acinetobacter baumannii to ICU was more than 50% except for cefoperazone sulbactam, and the detection rate of integron was 82.81%. The variable regions contained arr-3 + aacA4 and aacA4 + catB8 + aadA1 belongs to two class I integrons. Conclusion: The ICU multidrug-resistant Acinetobacter baumannii widely exists class Ⅰ integron, which mediates resistance to aminoglycosides, chloramphenicol and rifampicin, and is resistant to multidrug-resistant Acinetobacter baumannii in ICU Gene to be further tested.